United Therapeutics Corporation UTHR

475.45 3.24 0.69% as of 25 Sep
Market cap
$20.3B
P/E
15.7×
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

20.04% 19.71% 20.26% 19.32%
ROA
17.57% 17.51% 17.81% 17.33%
ROIC
24.42% 22.34% 23.94% 23.44%
Return on Tangible Assets
28.24% 27.40% 31.30% 27.28%
Average Days of Receivables
34.73 40.16 35.93 35.90
Free Cash Flow per Share
25.37 23.37 23.38 25.66
Free Cash Flow
1,111.20 1,035.20 1,016.90 1,093.00
Capital Expenditures
(445.00) (526.00) (546.40) (592.20)
Piotroski F-Score
7.00 7.00 6.00 4.00
Other line items
Cash ROIC
16.63% 15.59% 19.41% 18.60%
Accounts Receivable Turnover
9.78 10.11 10.00 9.15
Accounts Payable Turnover
0.86 0.92 0.98 0.94
Inventory Turnover
2.21 2.25 2.47 2.41
Average Days of Payables
478.62 463.37 427.65 415.59
Days of Inventory on Hand
180.51 173.86 153.02 161.80
Tax Rate
(0.24) (0.22) (0.20) (0.17)
Research and Development Expense of Revenue
17.40% 17.28% 17.01% 17.48%
Selling, General and Administrative Expense of Revenue
23.45% 23.75% 24.29% 24.22%
Share Based Compensation of Revenue
4.34% 4.64% 4.73% 4.93%
Interest Coverage
0.00 0.00 0.00 0.00
Operating CF/Net income
1.22 1.17 1.21 1.29
Depreciation/Fixed assets
0.05 0.05 0.05 0.05
Capex/Depreciation
(5.39) (6.14) (6.18) (6.47)
Revenue per Share
71.42 71.84 72.87 74.05
Operating CF per Share
35.53 35.24 35.94 39.56
Capex per Share
(10.16) (11.87) (12.56) (13.90)
Capex to Sales
0.14 0.17 0.17 0.19
Net Profit Margin
40.65% 41.94% 40.61% 41.56%

Fold the line items

Columns are period end dates